CD83与IL17RB附近变异对托法替布治疗中带状疱疹风险的贡献:全基因组关联研究荟萃分析结果
该研究对接受托法替布治疗的类风湿关节炎或银屑病患者进行全基因组关联研究荟萃分析,共纳入5246例受试者。在调整年龄、基线绝对淋巴细胞计数、遗传定义种族及甲氨蝶呤使用后,欧洲人群中CD83附近SNP与带状疱疹快速发作显著相关,跨种族荟萃分析中IL17RB附近SNP与带状疱疹快速发作显著相关。结论提示免疫相关基因CD83和IL17RB附近的流行变异可能贡献于托法替布治疗者的带状疱疹风险。
要点
- 欧洲人群中CD83附近SNP与托法替布治疗者带状疱疹快速发作显著相关。
- 跨种族荟萃分析中IL17RB附近SNP与带状疱疹快速发作显著相关(HR 3.6)。
- CD83与IL17RB风险等位基因频率在欧洲和东亚人群间差异显著。
核心结论
- 对托法替布治疗的RA或PsO患者遗传分析鉴定出多个与带状疱疹风险增加相关的位点。
- 欧洲和东亚人群中分别常见的CD83和IL17RB附近变异可能贡献于托法替布治疗者的带状疱疹风险。
研究设计与样本
- 研究为针对托法替布II期、III期及长期扩展研究中RA或PsO受试者的种族/适应症特异性、跨种族、跨人群全基因组关联研究荟萃分析。
- 使用Cox比例风险模型和逻辑回归分析分别评估带状疱疹事件时间和事件发生率(病例对照)。
主要发现
- 在调整年龄、基线绝对淋巴细胞计数、遗传定义种族及甲氨蝶呤使用(仅RA受试者)后,欧洲受试者中4个位点与带状疱疹快速发作显著相关(P < 5 × 10-8)。
- CD83附近SNP风险等位基因频率在欧洲受试者中约2%,在东亚受试者中约0.1%。
- 跨种族、跨人群荟萃分析中CD83 SNP仍显著,并鉴定出另外4个显著位点。
- IL17RB附近SNP与带状疱疹快速发作相关(荟萃分析风险比3.6 [95%置信区间2.40-5.44],P = 7.6 × 10-10)。
- IL17RB SNP风险等位基因频率在东亚受试者中约12%,在欧洲受试者中<0.2%。
关键数值与推荐
- 欧洲受试者中4个位点与带状疱疹快速发作显著相关,P < 5 × 10-8。
- IL17RB附近SNP荟萃分析风险比3.6(95%置信区间2.40-5.44),P = 7.6 × 10-10。
- CD83 SNP风险等位基因频率:欧洲约2%,东亚约0.1%。
- IL17RB SNP风险等位基因频率:东亚约12%,欧洲<0.2%。
临床怎么用
- 对于接受托法替布治疗的RA或PsO患者,可关注CD83和IL17RB附近变异以评估带状疱疹风险。
- 欧洲人群携带CD83风险等位基因者及东亚人群携带IL17RB风险等位基因者可能带状疱疹风险更高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA), psoriatic arthritis, and ulcerative colitis, and has been previously investigated for psoriasis (PsO). This meta-analysis of genome-wide association studies (GWAS) was performed to identify genetic factors associated with increased risk/faster onset of herpes zoster (HZ) in subjects with RA or PsO receiving tofacitinib treatment, and to determine potential mechanisms that could be attributed to the varying rates of HZ across ethnicities. METHODS: In an ethnicity/indication-specific, trans-ethnic, trans-population meta-analysis of GWAS in subjects with RA or PsO from phase II, phase III, and long-term extension studies of tofacitinib, 8 million genetic variants were evaluated for their potential association with time to an HZ event and incidence of an HZ event (case versus control) with tofacitinib treatment, using Cox proportional hazard and logistic regression analyses, respectively. RESULTS: In total, 5,246 subjects were included (3,168 with RA and 2,078 with PsO). After adjustment for age, baseline absolute lymphocyte count, genetically defined ethnicity, and concomitant methotrexate use (in RA subjects only), 4 loci were significantly associated with faster onset of HZ in European subjects (P < 5 × 10-8 ), including a single-nucleotide polymorphism (SNP) near CD83 (frequency of risk allele ~2% in European subjects versus ~0.1% in East Asian subjects). In the trans-ethnic, trans-population meta-analysis, the CD83 SNP remained significant. Four additional significant loci were identified in the meta-analysis, among which a SNP near IL17RB was associated with faster onset of HZ (meta-analysis hazard ratio 3.6 [95% confidence interval 2.40-5.44], P = 7.6 × 10-10 ; frequency of risk allele ~12% in East Asian subjects versus <0.2% in European subjects). CONCLUSION: Genetic analysis of tofacitinib-treated subjects with RA or PsO identified multiple loci associated with increased HZ risk. Prevalent variants near the immune-relevant genes CD83 and IL17RB in European and East Asian populations, respectively, may contribute to risk of HZ in tofacitinib-treated subjects.
引用
- Bing N, Zhou H, Chen X, et al. Contribution of a European-Prevalent Variant near CD83 and an East Asian-Prevalent Variant near IL17RB to Herpes Zoster Risk in Tofacitinib Treatment: Results of Genome-Wide Association Study Meta-Analyses. Arthritis Rheumatol. 2021. PMID: 33455090. doi:10.1002/art.41655
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。